Overview / Abstract: |
Retinal diseases are a leading cause of global vision impairment, driven by an increasing prevalence and the need for more effective treatment. Although clinical trials have shown promising results for various therapies, real-world application often yields less impressive outcomes due to factors like under-treatment and patient non-adherence. New and emerging therapies, particularly for conditions like diabetic macular edema (DME), diabetic retinopathy, and geographic atrophy (GA) secondary to age-related macular degeneration (AMD), aim to reduce the burden of frequent injections through innovative mechanisms and delivery systems. Recent advances include development of promising investigational treatments targeting various molecular pathways. In this CE activity, expert faculty review current and emerging treatment options for DME, DR, GA secondary to AMD, and other retinal diseases. They also assess the latest clinical trial data and real-world studies regarding the management of these conditions. |
Expiration |
Oct 30, 2025 |
Discipline(s) |
Optometry / Ophthalmology CE |
Format |
Podcast |
Credits / Hours |
1 |
Accreditation |
This continuing education activity is provided by Vindico Medical Education. |
Presenters / Authors / Faculty |
Arshad M. Khanani, MD, MA, FASRS David S. Boyer, MD Carl J. Danzig, MD, FASRS Eleonora (Nora) Lad, MD, PhD Carl D. Regillo, MD, FACS |
Sponsors / Supporters / Grant Providers |
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; AbbVie Inc.; Astellas; Apellis Pharmaceuticals, Inc.; Opthea; Alimera Sciences, Inc.; EyePoint Pharmaceuticals, Inc.; Neurotech Pharmaceuticals, Inc.; REGENXBIO Inc.; and Ocular Therapeutix, Inc. |
Keywords / Search Terms |
Vindico Medical Education DR, GA, New Mechanisms, and Noninvasive Treatments Free CE CME |